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Background: Patients with COPD have a high prevalence of anxiety and depression. The effi-
cacy of pulmonary rehabilitation (PR) in treating more severe anxiety and depression is
unknown. The study aimed to explore the effectiveness of PR in reducing symptoms of anxiety
and depression across a spectrum of severities.
Methods: The study used principles of comparative effectiveness research. Data was analysed
from 518 patients with COPD [57.5% male, mean (SD) age 69.2 years (8.8 years)]. Patients
were categorised into 3 groups based on their hospital anxiety and depression scale (HADS)
scores pre PR (‘none’ 0e7, ‘probable’ 8e10 and ‘presence’ 11e21). A responder was defined
as achieving a change of 48m on the incremental shuttle walk test (ISWT). Patients were ca-
tegorised as ‘completers’ if they attended their discharge assessment for PR.
Results: Anxiety and depression did not reduce following PR in patients with no symptoms
(p > 0.05). Patients with a ‘probable’ or ‘presence’ of symptoms had significant reductions
(both p < 0.001). There was a difference between sub-groups in change for anxiety and
depression with patients scoring highest on the HADS having the greatest reductions
(p < 0.001). There was no correlation between anxiety or depression and completion of PR
(p > 0.05). Responders and non-responders did not differ in their anxiety or depression levels
(p > 0.05).
Conclusion: PR is effective in reducing symptoms of anxiety and depression. Previous studies
may have underestimated the effectiveness of the PR programme in improving mood.
ª 2011 Elsevier Ltd. All rights reserved.C Rehabilitation Theme, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Groby Road,
el.: þ44 116 258 3652; fax: þ44 116 2563149.
@uhl-tr.nhs.uk (S.L. Harrison).
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Chronic obstructive pulmonary disease (COPD) is a multi-
system disease, causing dyspnoea and reduction in physical
activity, limiting everyday tasks.1,2 This may be associated
with psychosocial co-morbidities including symptoms of
anxiety and depression.
It is accepted that patients with COPD have a high
prevalence of symptoms of anxiety and depression
compared to that of the healthy population.3,4 Estimates
for the prevalence of anxiety and depression in patients
with COPD are 36% and 40% respectively, although these
figures are wide ranging (7%e46% for depression and up to
49% for anxiety) due to the variety in screening tools and
classification.5
Importantly, increased symptoms of anxiety and
depression have been associated with a number of adverse
health outcomes in patients with COPD including; physical
and functional impairment, increased symptoms, an
increased risk of mortality, a reduction in quality of life, an
increased risk of exacerbation and an increase in health-
care utilisation.6e12
Pulmonary Rehabilitation (PR) is central to the manage-
ment of patients with COPD and the efficacy of the inter-
vention in this patient group is widely recognised.13,14 It has
been recommended that part of the role of PR is to provide
psychosocial support.14 Despite the documented benefits of
PR, 20e40% of patients do not complete the programme.15,16
This leads to an inefficient use of valuable health resources.
Sociodemographic data andclinical variables todatehavenot
been successful in predicting patient drop out in PR and
psychosocialmeasuresmayhave a greater predictive value.15
The Hospital Anxiety and Depression Scale (HADS)17 is
a frequently-used tool to assess anxiety and depression in
patients with COPD and serves as an outcome measure in PR
programmes.18 To date, no studies have examined the
relationship between those patients who drop out of PR and
their baseline HADS score.
In addition to the issue of drop out there is evidence that
approximately 30% of patients achieve little or no clinical
benefit in terms of either health status or exercise perfor-
mance.16 No clear variables appear predictive of improve-
ment in exercise performance or health status following
a PR programme.16 The affect of anxiety on health
outcomes has not analysed in response to a PR programme.
It therefore remains unclear how symptoms of anxiety, may
relate to a patient’s ability to achieve a clinically mean-
ingful improvement in exercise performance following PR.
The aims of this study were to explore the effectiveness
of PR in reducing symptoms of anxiety and depression
across a spectrum of severities. A secondary objective is to
examine the influence of symptoms of anxiety and
depression on the outcomes of PR and specifically on drop
out rates and improvement in exercise performance.
Methods
Study design
The study used principles of comparative effectiveness
research.19 Data was collected on patients who attendedtheir initial assessment for an outpatient PR programme at
a single centre (Glenfield Hospital, Leicester, UK) between
January 1999 and January 2010. Patients gave consent for
their data to be recorded on the PR database.
Study population
A total of 518 patients were identified from the database
using the inclusion criteria.
Criteria for inclusion in the analysis were; a physician
confirmed diagnosis of COPD, obstructive spirometry
(Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stage 2) and a recorded HADS score.
The Hospital Anxiety and Depression Scale (HADS)
We analysed anxiety and depression subscales of the HADS
separately. We categorised the patients into 3 predefined
and validated groups based on their HADS scores pre
PR (‘none’ 0e7, ‘probable’ 8e10 and ‘presence’ 11e21).17
The MCID for a change in each subscale has been quoted
as 1.5.20
Chronic Respiratory Questionnaire e Self reported
(CRQ-SR)
The CRQ-SR was divided into the four dimensions of dysp-
noea, fatigue, emotional function, and mastery. Once
averaged the score for each domain range between 1 and 7
with a lower score indicating better health status.21 This
measure has been found to be a valid and reliable measure
of health status in patients with COPD.22 MCID for a change
in each domain has previously been described as 0.5.23
The Incremental Shuttle Walk Test (ISWT)
The ISWT is a field based walking test frequently used as an
outcome measure in PR and has been shown to be related
to VO2 max.
24 The test was repeated after a 30 min rest.
Peak distance achieved was recorded.
The Pulmonary Rehabilitation Programme
The outpatient PR programme was delivered by a multidis-
ciplinary team. Patients were required to attend twice
a week for 7 weeks. Sessions consisted of an exercise pro-
gramme and patient education. The exercise programme
involved endurance training in the form of walking and
stationary cycling and strength exercises. The outpatient
PR programme has been previously described.25
Data collection
Data was recorded at the time of the patient’s initial
assessment for a PR programme and again at their discharge
appointment following completion of the PR programme.
Patients were divided into ‘completers’ and ‘drop-outs’.
We applied a very strict criteria and the latter was defined
as those who did not attend their discharge assessment
following PR. Patients who completed the PR programme
840 S.L. Harrison et al.were then further subdivided into ‘responders’ and ‘non-
responders’. ‘Responders’ were defined as improving by at
least the minimal clinically important difference (MCID) of
the incremental shuttle walk test (ISWT) following PR,
previously defined as 48m.26
Statistical analysis
Analyses were carried out using SPSS statistics (version 18,
Chicago). A paired t-test was conducted on those who
completed the PR programme to analyse the effect of PR on
anxious anddepressed symptoms asmeasuredby theHADS.To
analyse the effectiveness of PR in reducing anxiety and
depression in patients with various severities of symptoms
(‘none’, ‘probable’, ‘presence’) an ANOVA with a Bonferroni
post-hoc analysis was applied to look at the differences in
change in HADS scores between groups. Due to multiple
comparisonspost-hocsignificance levelswere set atp<0.017.
Characteristics betweenPRcompleters anddrop-outswere
compared using independent t-tests for continuous data and
chi squared for categorical data. Correlations between base-
line characteristics and completion or drop out and baseline
characteristics and responders or non-responders were iden-
tified using Pearson Correlation coefficient.
Results
Patient population
518 patients (57.5% male) with a mean (SD) age of 69.2 years
(8.8 years) were categorised into the 3 predefined HADS
sub-groups (‘none’, ‘probable’ and ‘presence’). The preva-
lence for symptoms of anxiety was 48.5%, 24.3% and 27.2%
and for symptoms of depression was 60.9%, 21.7% and 17.4%
respectively. There were no significant differences between
any baseline variables for the 3 sub-groups (Table 1).
The effect of PR on anxiety and depression
The mean (SD) HADS score for patients who completed the
programme reduced from 7.99 (4.10) to 6.72 (3.72) for
anxiety and 6.80 (3.56) to 5.74 (3.45) for depression (both
p < 0.001). Although statistically significant, the reduction
in anxiety (1.27) and in depression (1.06) for the total group
in both subscales did not reach the MCID.
Figs. 1 and 2 display the effectiveness of PR in reducing
anxiety and depression in patients with various severities of
symptoms. There was no significant difference in anxiety or
depression following PR in patients with no evidence of
anxiety or depression (none: anxiety mean change (SE) 0.99
(0.19), depression 0.25 (0.14), pgt; 0.05). However for
patients who demonstrated symptoms of anxiety or
depression (a probable or presence of anxiety or depres-
sion) had significantly reduced levels of anxiety and
depression post PR (probable: anxiety 1.78 (0.27)),
depression 1.71 (0.34), presence: anxiety 3.11 (0.35),
depression 3.19 (0.47) (both p < 0.001). This reduction in
anxiety and depression was clinically significant.
There were significant differences between sub-groups
in change for both anxiety and depression (p < 0.001). Post-hoc analysis demonstrated significant differences between
all sub-groups for both anxiety and depression (all
p < 0.004). There were no significant differences between
sub-groups in change in ISWT distance or any of the CRQ-SR
domains following PR (pgt; 0.05).
The influence of symptoms of anxiety and
depression on drop-out
Of the 518 patients who attended their initial assessment
for PR 184 dropped out (35.5%). Completers and drop-outs
did not differ significantly in any of the baseline variables
except pre ISWT distance (p Z 0.003) (drop-outs 180m,
completers 220m).
There was no correlation between either HADS anxiety
score (pgt; 0.05) or HADS depression score (pgt; 0.05) and
completion of PR. The HADS subscales correlated highly
with each other (r Z 0.59, p < 0.001). A weak correlation
was found between completion and pre ISWT distance
(r Z 0.13, p < 0.05) and CRQ-SR fatigue (r Z 0.26,
p < 0.05).
The influence of symptoms of anxiety and
depression on exercise performance
334 patients completed the PR programme. 197 (59%)
achieved an improvement of 48m on the ISWT. There was
no significant difference between responders and non-
responders in anxiety or depression (pgt; 0.05). Significant
differences did exist between responders and non-
responders in age (responders 68.42 years (SD 8.56), non-
responders 70.92 years (7.71), p Z 0.007). (Table 2).
Discussion
This is the first study to examine the effect of PR on
symptoms of anxiety and depression across a spectrum of
severities. Our results show that following PR HADS scores
are significantly reduced in those patients who present with
symptoms of anxiety and/or depression at baseline.
Symptoms of anxiety and depression are high in COPD
patients and our study population is similar to previous
studies.27 A recent study explored the prevalence of
symptoms using the HADS. Anxiety scores 10 points were
identified in 32% of patients and depression scores 10
points were present in 27%. These results can be compared
with our population where anxiety and depression scores
11 points17 were identified in 27.2% and 17.4% respec-
tively.28 Although this study was conducted in a pulmonary
rehabilitation cohort they did not explore the effect of PR
on different severities of anxiety and depression.
Previous research summarised by a meta-analysis has
described the effects of PR on symptoms of anxiety and
depression in COPD. However, the mean scores were either
within the normal range or patients had only mild symp-
toms.27 As a result it was only possible to interpret the
effects of PR on reducing levels of anxiety and depression in
those patients with mild symptoms. The efficacy of PR in
treating more severe symptoms of anxiety and depression
remained unproven.29 Our results suggest that the biggest
Table 1 Baseline variables for the total population and each subgroup.
Total group
(n Z 518)
None Probable Presence
Anxiety Depression Anxiety Depression Anxiety Depression
Gender (% male) 57.49% 58.58% 58.28% 61.90% 56.36% 60.28% 69.32%
Age 69.23 (8.80) 69.57 (8.63) 69.30 (8.50) 69.12 (9.50) 69.77 (8.96) 68.70 (8.49) 68.28 (9.60)
FEV1 % Predicted 39.89 (15.10) 39.68 (15.21) 39.50 (14.55) 40.24 (16.42) 41.46 (16.32) 39.94 (13.73) 39.06 (1542)
MRC 4 IQR 3e4 4 IQR 3e5 3 IQR 3e4 3 IQR 3e4 3 IQR 3e4 4 IQP 3e5 4 IQR 3e5
BMI 26.24 (5.69) 26.20 (5.99) 26.00 (5.96) 25.88 (5.36) 25.92 (5.16) 26.64 (5.43) 27.12 (5.48)
Pack years 41.67 (24.64) 43.55 (25.01) 42.85 (23.79) 42.66 (23.71) 39.44 (26.73) 42.66 (23.71) 42.21 (24.15)
Social status
(% living alone)
27.66% 27.54% 29.02% 28.85% 26.19% 26.79% 24.66%
ISWT (m) 208.32
(130.95)
200.91
(137.42)
206.15
(132.90)
209.09
(115.12)
210.09
(120.72)
220.43
(132.23)
211.49
(138.61)
CRQ-SR Dyspnoea 2.35 (0.93) 2.30 (0.95) 2.28 (0.94) 2.42 (0.87) 2.48 (0.94) 2.37 (0.96) 2.45 (0.95)
CRQ-SR Fatigue 3.29 (1.29) 3.22 (1.32) 3.23 (1.29) 3.40 (1.30) 3.40 (1.26) 3.33 (1.24) 2.45 (0.95)
CRQ-SR Emotion 4.19 (1.25) 4.10 (1.23) 4.12 (1.28) 4.18 (1.26) 4.20 (1.28) 4.40 (1.26) 4.34 (1.22)
CRQ-SR Mastery 4.21 (1.35) 4.11 (1.33) 4.13 (1.35) 4.28 (1.40) 4.31 (1.37) 4.34 (1.32) 4.29 (1.30)
FEV1 Z Forced Expiratory Volume in 1 s; MRC Z Medical Research Council; BMI Z Body Mass Index; IQR Z Interquartile Range.
ISWT Z Incremental Shuttle Walk Test; CRQ-SR Z Chronic Respiratory Questionnaire-self reported.
The efficacy of PR in reducing HADS 841reduction in HADS scores following PR occurred in the group
of patients displaying the most severe symptoms of anxiety
and depression.
Furthermore, we found that patients, whose baseline
HADS score was below the threshold indicating symptoms
of anxiety and depression did not have a significantFigure 1 HADS anxiety score pre and post pulmonary reha-
bilitation in 3 groups categorised according to baseline HADS
anxiety score: ‘none 0e7’, ‘probable’ 8e10 and ‘presence’
11e21.change in symptoms following PR. These results indicate
that previous studies examining the effect of PR on
symptoms of anxiety and depression in all patients with
COPD including those with no symptoms or very mild
symptoms may have underestimated the effectiveness of
the PR programme.Figure 2 HADS depression score pre and post pulmonary
rehabilitation in 3 groups categorised according to baseline
HADS depression score: ‘none 0e7’, ‘probable’ 8e10 and
‘presence’ 11e21.
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842 S.L. Harrison et al.Due to the multi-factorial nature of a PR programme we
cannot conclude which components have contributed to
a reduction in symptoms of anxiety and depression. We
suspect that in addition to the benefits of exercise on
reducing physical impairment, the education component
increases coping skills and social support may also play an
important role.
Whilst this study showed that PR significantly reduced
symptoms of anxiety and depression in those with a HADS
score of 11 a percentage of patients still had HADS scores
8 following PR. This suggests that some patients may
require additional interventions to reduce their symptoms
of anxiety and depression to within the normal range.
We already know that a high percentage of patients do
not complete PR and our results support this.15,16 Our drop
out rate is slightly higher than some previously reported.16
However, the definition of a completer often varies. We
applied strict criteria; patients were required to attend
their follow up appointment to be classified as a completer.
Our results did not show symptoms of depression to be
a predictor of drop out. This is different from Garrod
et al.’s who reported the risk of drop out to be higher in
depressed patients.16 However they classified patients
using the BASDEC rather than the HADS. The wide range of
tools used to screen for symptoms of anxiety and depres-
sion makes it difficult to reach a consensus regarding the
characteristics of patients with symptoms.18 However, the
HADS has been reported to be the most frequently-used
tool in patients with COPD.18
We found only a weak correlation between fatigue and
drop out from PR. Previously one study has reported the St
Georges Respiratory Questionnaire (SGRQ) to predict drop
out (p Z 0.02). This study included a much smaller sample
size.16
In terms of exercise capacity patients were significantly
more likely to drop out of the PR programme if they were
more disabled. More disabled patients were more likely to
improve their exercise performance following PR. Cilione
et al. (2002) also found that lower initial walking distance
was predictive of a greater change in walking distance after
rehabilitation.30
Recently anxiety has been found to be related to poorer
health outcomes including sub-maximal exercise tolerance
in patients with COPD.31,32 We found that baseline symp-
toms of anxiety and depression screened for using the HADS
did not influence improvement in exercise performance
following PR and similar findings were reported by Garrod
et al.16
Our findings indicated that symptoms of anxiety and
depression do not influence the likelihood of patients
successfully completing PR nor do they affect clinical
outcomes. This implies that the delivery of psychological
support designed to reduce symptoms of anxiety and
depression may not be necessary before PR. Instead an
intervention could run alongside or afterwards with
a focused population of patients identified as having
symptoms of anxiety and/or depression despite completing
PR. Targeting treatment to patients needs is a cost effec-
tive patient-centred approach to delivering patient care.
The results from our large cohort are not supportive of
previous findings that high levels of depression predict drop
out from PR.16,33 The variability in results highlights the
The efficacy of PR in reducing HADS 843complexity of this issue. Reasons for drop out have been
described in qualitative research.34e36 Perhaps a more
sophisticated tool is required to screen for patients likely
not to complete a programme. Patient’s beliefs relating to
the effectiveness of treatment have been found to be
a predictor of attendance and drop out from a PR pro-
gramme15,33 and interventions designed to shape illness
perceptions have been shown to be useful in increasing
attendance in other populations.37
We acknowledge some limitations with our study. Larger
changes were seen in groups with higher HADS scores. This
could be an effect of regression to the mean, but this
pattern is clinically understandable. We cannot make any
inferences regarding the long term effects of PR on symp-
toms of anxiety and depression measured using the HADS.
PRappears tobeeffective in reducingsymptomsofanxiety
and depression. By including patients with no symptoms
previous studies may have underestimated the effectiveness
of the PR programme in reducing anxiety and depression.
Ethics approval
This study was assessed as being a service evaluation by the
chair of the LNR Research Ethics Committee in Nottingham,
UK and therefore was not required to have an ethical
approval under the NHS research governance arrangements.Funding
“This report/article presents independent research
commissioned by the National Institute for Health Research
(NIHR). The views expressed in this publication are those of
the author(s) and not necessarily those of the NHS, the
NIHR or the Department of Health.”
Conflicts of interest
SH, NG, JW, MM, MS, SS have no actual or potential conflicts
of interest.
References
1. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR,
Wedzicha JA. Exacerbations and time spent outdoors in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2005
Mar 1;171(5):446e52.
2. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M,
Gosselink R. Quantifying physical activity in daily life with
questionnaires and motion sensors in COPD. Eur Respir J 2006
May;27(5):1040e55.
3. van EL, Yzermans CJ, Brouwer HJ. Prevalence of depression in
patients with chronic obstructive pulmonary disease:
a systematic review. Thorax 1999 Aug;54(8):688e92.
4. Karajgi B, Rifkin A, Doddi S, Kolli R. The prevalence of anxiety
disorders in patients with chronic obstructive pulmonary
disease. Am J Psychiatry 1990 Feb;147(2):200e1.
5. Yohannes AM, Baldwin RC, Connolly MJ. Mood disorders in
elderly patients with chronic obstructive pulmonary disease.
Rev Clin Gerontol 2000;10(02):193e202.
6. Kim HFS, Kunik ME, Molinari VA, Hillman SL, Lalani S,
Orengo CA, et al. Functional impairment in COPD patients: theimpact of anxiety and depression. Psychosomatics 2000 Dec 1;
41(6):465e71.
7. Brenes GA. Anxiety and chronic obstructive pulmonary disease:
prevalence, impact, and treatment. Psychosom Med 2003 Nov;
65(6):963e70.
8. Egede LE. Major depression in individuals with chronic medical
disorders: prevalence, correlates and association with health
resource utilization, lost productivity and functional disability.
Gen Hosp Psychiatry 2007 Sep;29(5):409e16.
9. Yohannes AM, Roomi J, Waters K, Connolly MJ. Quality of life in
elderly patients with COPD: measurement and predictive
factors. Respir Med 1998 Oct;92(10):1231e6.
10. Yohannes AM, Roomi J, Connolly MJ. Elderly people at home
disabled by chronic obstructive pulmonary disease. Age Ageing
1998 Jul;27(4):523e5.
11. Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1-year
mortality in patients discharged from hospital following acute
exacerbation of chronic obstructive pulmonary disease. Age
Ageing 2005 Sep;34(5):491e6.
12. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, et al.
Independent effect of depression and anxiety on chronic
obstructive pulmonary disease exacerbations and hospitali-
zations. Am J Respir Crit Care Med 2008 Nov 1;178(9):
913e20.
13. National Institute for Clinical Excellence. Clinical guideline
101: chronic obstructive pulmonary disease e management of
chronic obstructive pulmonary disease in adults in primary and
secondary care 21.06.2010. Ref Type: Generic.
14. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N,
Bourbeau J, et al. American Thoracic Society/European
Respiratory Society statement on pulmonary rehabilitation. Am
J Respir Crit Care Med 2006 Jun 15;173(12):1390e413.
15. Fischer MJ, Scharloo M, Abbink JJ, van ’t Hul AJ, van RD,
Rudolphus A, et al. Drop-out and attendance in pulmonary
rehabilitation: the role of clinical and psychosocial variables.
Respir Med 2009 Oct;103(10):1564e71.
16. Garrod R, Marshall J, Barley E, Jones PW. Predictors of success
and failure in pulmonary rehabilitation. Eur Respir J 2006 Apr;
27(4):788e94.
17. Zigmond AS, Snaith RP. The hospital anxiety and depression
scale. Acta Psychiatr Scand 1983 Jun;67(6):361e70.
18. Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depres-
sion and anxiety in chronic heart failure and chronic obstruc-
tive pulmonary disease: prevalence, relevance, clinical
implications and management principles. Int J Geriat Psychi-
atry 2010;25(12):1209e21.
19. Tinetti ME, Studenski SA. Comparative effectiveness research
and patients with multiple chronic conditions. N Engl J Med
2011 Jun 30;364(26):2478e81.
20. Puhan MA, Frey M, Buchi S, Schunemann HJ. The minimal
important difference of the hospital anxiety and depression
scale in patients with chronic obstructive pulmonary disease.
Health Qual Life Outcomes 2008;6:46.
21. Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD.
Development of a self-reported chronic respiratory question-
naire (CRQ-SR). Thorax 2001 Dec;56(12):954e9.
22. Williams JE, Singh SJ, Sewell L, Morgan MD. Health status
measurement: sensitivity of the self-reported chronic respi-
ratory questionnaire (CRQ-SR) in pulmonary rehabilitation.
Thorax 2003 Jun;58(6):515e8.
23. Jaeschke R, Singer J, Guyatt GH. Measurement of health
status. Ascertaining the minimal clinically important differ-
ence. Control Clin Trials 1989 Dec;10(4):407e15.
24. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Devel-
opment of a shuttle walking test of disability in patients with
chronic airways obstruction. Thorax 1992 Dec;47(12):1019e24.
25. Sewell L, Singh SJ, Williams JE, Collier R, Morgan MD. How long
should outpatient pulmonary rehabilitation be? A randomised
844 S.L. Harrison et al.controlled trial of 4 weeks versus 7 weeks. Thorax 2006 Sep;
61(9):767e71.
26. Singh SJ, Jones PW, Evans R, Morgan MD. Minimum clinically
important improvement for the incremental shuttle walking
test. Thorax 2008 Sep;63(9):775e7.
27. Coventry PA, Hind D. Comprehensive pulmonary rehabilitation
for anxiety and depression in adults with chronic obstructive
pulmonary disease: systematic review and meta-analysis. J
Psychosom Res 2007 Nov;63(5):551e65.
28. Janssen DJ, Spruit MA, Leue C, Gijsen C, Hameleers H,
Schols JM, et al. Symptoms of anxiety and depression in COPD
patients entering pulmonary rehabilitation. Chronic Respir Dis
2010 Aug 1;7(3):147e57.
29. Coventry PA. Does pulmonary rehabilitation reduce anxiety
and depression in chronic obstructive pulmonary disease? Curr
Opin Pulm Med 2009 Mar;15(2):143e9.
30. Cilione C, Lorenzi C, Dell OD, Garuti G, Rossi G, Totaro L, et al.
Predictors of change in exercise capacity after comprehensive
COPD inpatient rehabilitation. Med Sci Monit 2002 Nov;8(11):
CR740e5.
31. Eisner MD, Blanc PD, Yelin EH, Katz PP, Sanchez G, Iribarren C,
et al. Influence of anxiety on health outcomes in COPD. Thorax
2010 Mar;65(3):229e34.32. von LA, Taube K, Lehmann K, Fritzsche A, Magnussen H. The
impact of anxiety and depression on outcomes of pulmonary
rehabilitation in patients with COPD. Chest 2011 Sep;140(3):
730e6.
33. Fan VS, Giardino ND, Blough DK, Kaplan RM, Ramsey SD. Costs
of pulmonary rehabilitation and predictors of adherence in the
National Emphysema Treatment Trial. COPD 2008 Apr;5(2):
105e16.
34. Arnold E, Bruton A, Ellis-Hill C. Adherence to pulmonary
rehabilitation: a qualitative study. Respir Med 2006 Oct;
100(10):1716e23.
35. Fischer MJ, Scharloo M, Abbink JJ, Thijs-Van A, Rudolphus A,
Snoei L, et al. Participation and drop-out in pulmonary reha-
bilitation: a qualitative analysis of the patient’s perspective.
Clin Rehabil 2007 Mar;21(3):212e21.
36. Sabit R, Griffiths TL, Watkins AJ, Evans W, Bolton CE, Shale DJ,
et al. Predictors of poor attendance at an outpatient pulmo-
nary rehabilitation programme. Respir Med 2008 Jun;102(6):
819e24.
37. Petrie KJ, Cameron LD, Ellis CJ, Buick D, Weinman J. Changing
illness perceptions after myocardial infarction: an early
intervention randomized controlled trial. Psychosom Med 2002
Jul;64(4):580e6.
